Plexxikon Inc. v. Novartis Pharmaceuticals Corporation

District Court, N.D. California·Decided March 20, 2020·No. 4:17-cv-04405·Unknown

Opinion

PLEXXIKON INC., Case No. 17-cv-04405-HSG

Plaintiff, ORDER GRANTING IN PART AND DENYING IN PART MOTION TO v. STRIKE DEFENDANT’S DAUBERT MOTIONS CORPORATION, Re: Dkt. No. 236 Defendant. Pending before the Court is Plaintiff Plexxikon Inc.’s motion to strike Defendant Novartis Pharmaceutical Corporation’s Daubert motions. See Dkt. No. 236. The Court held a hearing on November 1, 2019. Dkt. No. 337. As indicated during the hearing, and as detailed further below, the Court GRANTS IN PART and DENIES IN PART the motion. Plaintiff challenges the timeliness of Defendant’s four Daubert motions, filed on June 6, 2019. See Dkt. Nos. 200, 202, 204, 206. In the alternative, Plaintiff seeks to strike a declaration filed in support of one of the Daubert motions. See Dkt. No. 200-1. The Court addresses each argument in turn. A. Motion to Strike Daubert Motions for Timeliness Plaintiff first seeks to strike all of Defendant’s Daubert motions as untimely. See Dkt. No. 236. In doing so, Plaintiff invokes the Court’s inherent authority to manage its docket. See, e.g., Landis v. N. Am. Co., 299 U.S. 248, 254 (1936) (recognizing the power “inherent in every court to control the disposition of the causes on its docket with economy of time and effort for itself, for counsel, and for litigants”). Plaintiff urges that Defendant’s June 6 Daubert motions contravene at On June 20, 2018, the Court issued a revised scheduling order setting the deadline for hearing dispositive motions as June 20, 2019, and setting trial to begin on October 7, 2019. See Dkt. No. 80. The schedule did not include a deadline for non-dispositive motions generally, or Daubert motions more specifically. Id. On May 21, 2019, the Court directed Defendant to file its dispositive motion by May 23, 2019, and continued the hearing on the parties’ dispositive motions. See Dkt. No. 173. Again, the order was silent as to the timing of non-dispositive motions. On May 28, 2019, the Court granted Plaintiff’s motion to extend its time to respond to Defendant’s pending motions. See Dkt. No. 183. The order adopted Plaintiff’s proposal—and language—to extend Plaintiff’s deadline to file oppositions to Defendant’s “dispositive and non- dispositive motions,” as well as the corresponding reply deadline. Id.; see also Dkt. No. 180-6 (Proposed Order). The order also continued the hearing on the non-dispositive motions to August 29, 2019. See id. The order did not set a deadline for the filing of further non-dispositive motions. Indeed, none of these orders set a non-dispositive motion or Daubert motion deadline. The Court’s Civil Pretrial and Trial Standing Order states that “[m]otions in limine cannot be used to request summary judgment or raise Daubert challenges unless the Court has specifically granted prior approval.” See Civil Pretrial and Trial Standing Order ¶ 24. The Court’s general practice is to hear Daubert motions on or before the dispositive motions hearing deadline. However, the Court acknowledges that there is ambiguity in its standing order regarding when to file Daubert motions. The Court will not penalize Defendant based on a non-explicit deadline, particularly here where Plaintiff had ample time to oppose and argue the merits of Defendant’s Daubert motions. The Court DENIES Plaintiff’s motion to strike Defendant’s Daubert motions on this basis. B. Motion to Strike Expert Declaration One of Defendant’s June 6 Daubert motions, directed to the opinions of Plaintiff’s expert Dr. Michael L. Metzker, was supported by a declaration from Defendant’s expert, Dr. Phil Baran. See Dkt. No. 199-6. Plaintiff seeks, in the alternative, to strike Dr. Baran’s declaration in its entirety as an untimely supplemental expert report. See Dkt. No. 236 at 4. written report, “a complete statement of all opinions the witness will express” at trial, and the basis and reasons for them. See Fed. R. Civ. P. 26(a)(2)(B)(i). Rebuttal disclosures of expert testimony are “intended solely to contradict or rebut evidence on the same subject matter identified by another party” in its expert disclosures. See Fed. R. Civ. P. 26(a)(2)(D)(ii). Rule 26 further provides that these disclosures be made at the times directed by the Court. See Fed. R. Civ. P. 26(a)(2)(D). Rule 37, in turn, provides that if a party fails to provide the information required by Rule 26(a), “the party is not allowed to use that information or witness to supply evidence on a motion, at a hearing, or at a trial, unless the failure was substantially justified or harmless.” Fed. R. Civ. P. 37(c)(1). The Court has “particularly wide latitude . . . to issue sanctions under Rule 37(c)(1).” Yeti by Molly, Ltd. v. Deckers Outdoor Corp., 259 F.3d 1101, 1106 (9th Cir. 2001). Here, Defendant acknowledges that Dr. Baran’s declaration contains some arguments and analysis not previously disclosed in his rebuttal report. See, e.g., Dkt. No. 247 at 7, 9–12. Defendant also appears to acknowledge—as it must—that Dr. Baran’s declaration was submitted after the close of expert discovery. See Dkt. No. 80 (setting May 2, 2019, as the deadline for expert discovery). However, Defendant urges that this new information was solely in response to Dr. Metzker’s reply expert report, submitted on April 11, 2019, and Dr. Metzker’s deposition testimony, taken on May 1, 2019. See id. at 7. As such, Defendant explains that Dr. Baran could not have included these arguments in his March 14, 2019, rebuttal expert report. Defendant contends that Dr. Baran’s declaration is thus an appropriate supplement under Rule 26(e)(2), and even if the Court disagrees with this characterization, Dr. Baran’s declaration is substantially justified and harmless and should not be precluded under Rule 37. As the Ninth Circuit has explained, “[R]ule 26(e) creates a “duty to supplement,” but “not a right” to do so. See Luke v. Family Care & Urgent Med. Clinics, 323 Fed. App’x 496, 500 (9th Cir. 2009). The Ninth Circuit has cautioned that Rule 26(e) is not “a loophole through which a party who submits partial expert witness disclosures, or who wishes to revise [its] disclosures in light of [its] opponent’s challenges to the analysis and conclusions therein, can add to them to [its] Inc., 52 F. Supp. 3d 973, 983–84 (N.D. Cal. 2014) (“Although Rule 26(e) obliges a party to supplement or correct its disclosures upon information later acquired, this does not give license to sandbag one’s opponent with claims and issues which should have been included in the expert witness’ report . . . .” (quotation omitted)). The Court is particularly alert to such gamesmanship where, as here, Defendant submitted the additional expert material in conjunction with its Daubert motions, and only after expert discovery had closed. The supplementation requirement is only intended to “correct[] inaccuracies, or fill[] the interstices of an incomplete report based on information that was not available at the time of the initial disclosure.”1 Id. (quotation omitted). The Court, therefore, looks closely at Dr. Baran’s declaration to determine what additions are derived from new information contained in Dr. Metzker’s reply report and his deposition. At a high level, Dr. Baran’s declaration, much like his rebuttal report, seeks to explain why Dr. Metzker’s education and experience are insufficient to qualify him as

Free access — add to your briefcase to read the full text and ask questions with AI

Plexxikon Inc. v. Novartis Pharmaceuticals Corporation, (N.D. Cal. 2020).

Plexxikon Inc. v. Novartis Pharmaceuticals Corporation (Plexxikon Inc. v. Novartis Pharmaceuticals Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Landis v. North American Co.
299 U.S. 248 (Supreme Court, 1936)
Yeti by Molly Ltd. v. Deckers Outdoor Corp.
259 F.3d 1101 (Ninth Circuit, 2001)
Mariscal v. Graco, Inc.
52 F. Supp. 3d 973 (N.D. California, 2014)